MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc., a company developing protein and antibody therapeutics, will present new data from its pre-clinical anti-CD19 and anti-CD40 programs, XmAb®5574 and XmAb®5485 respectively, for lymphoma and leukemias at the 50th Annual Meeting of the American Society of Hematology being held at the Moscone Convention Center in San Francisco December 6-9, 2008.
